Please login to the form below

Not currently logged in
Email:
Password:

Theravance

This page shows the latest Theravance news and features for those working in and with pharma, biotech and healthcare.

J&J takes option on Theravance’s JAK drug in $1bn deal

J&J takes option on Theravance’s JAK drug in $1bn deal

Theravance, but will wait for the results of the trials before deciding whether to opt in. ... associated with systemic JAK exposure," said Theravance’s CEO Rick Winningham, who thinks that this could allow the dose of TD-1743 to be hiked to boost

Latest news

More from news
Approximately 10 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    HuTARG research platform for biologics against challenging targets. collaboration. 150. Theravance Biopharma/ Takeda Pharmaceutical.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Care and a chronic obstructive pulmonary disease (COPD) drug-development pact with Theravance. ... In ex-US markets (apart from China), Mylan will be responsible for the development as well as commercialisation of the product and Theravance will receive

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Ireland. 2014. Endo. Paladin. Ireland. 2014. Theravance Biopharma. Cayman Islands. 2014.

  • Pharma deals during June 2013 Pharma deals during June 2013

    elected not to close the various deals on offer as noted in aie the Theravance, AOP Orphan and the Speranza ELND005 transactions.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Theravance hires BMS veteran Pasqualone Theravance hires BMS veteran Pasqualone

    Pasqualone joins Theravance as the company at a crucial time as its development deals with GlaxoSmithKline bears fruit with US approval of respiratory treatment Anoro Ellipta. ... This followed the approval last year of Theravance's antibiotic Vibativ

  • Jeff Jonker joins Theravance Jeff Jonker joins Theravance

    Jeff Jonker joins Theravance. He has experience at Genentech. Theravance has appointed Jeff Jonker as senior VP, corporate and business development. ... Jeff brings a wealth of industry and deal experience to Theravance,” said Winningham.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics